Education
About Us
Working with TipRanks
Follow Us
Novartis Ag (DE:NOTA)
FRANKFURT:NOTA
NOTA Stock Chart & Stats
Day’s Range― - ―
52-Week Range€85.60 - €108.50
Previous CloseN/A
Volume500.00
Average Volume (3M)32.00
Market Cap
$205.81B
Enterprise Value€212.89B
Total Cash (Recent Filing)$11.46B
Total Debt (Recent Filing)$31.26B
Price to Earnings (P/E)18.7
Beta0.36
Next Earnings
Apr 29, 2025EPS Estimate
1.96Next Dividend Ex-Date
Mar 12, 2025Dividend Yield2.93%
Share Statistics
EPS (TTM)5.47
Shares Outstanding2,189,930,400
10 Day Avg. Volume27
30 Day Avg. Volume32
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)N/A
Price to Sales (P/S)4.16
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap1.03
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.47
Enterprise Value/Ebitda10.26
Forecast
1Y Price Target
€120.36Price Target Upside17.42% Upside
Rating ConsensusHold
Number of Analyst Covering1
---
Bulls Say, Bears Say
Bulls Say
Company StrategyNovartis is focusing on entering less competitive areas with moderate-sized opportunities as part of its immunology strategy.
Product DevelopmentCosentyx is maintaining its NBRx share despite increased competition and is expected to grow further with the approval of the HS indication and IV formulation.
Trial ResultsKisqali's NATALEE trial results have received positive feedback from physicians, indicating excitement for its use among eBC patients.
Bears Say
Market ChallengesThe target price implies modest upside from current levels, suggesting that revenue upside is mostly priced in.
Pricing StrategyIRA-related price cuts appear manageable but also noted that the 9-year price setting for small molecules vs the 13-year price setting for biologics is an issue that potentially impacts portfolio decisions.
Regulatory ChallengesIRA-related price cuts appear manageable but also noted that the 9-year price setting for small molecules vs the 13-year price setting for biologics is an issue that potentially impacts portfolio decisions in favor of biologics.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
1.69% Mutual Funds
2.68% Other Institutional Investors
95.37% Public Companies and Individual Investors
NOTA FAQ
What was Novartis Ag’s price range in the past 12 months?
Novartis Ag lowest stock price was €85.60 and its highest was €108.50 in the past 12 months.
What is Novartis Ag’s market cap?
Novartis Ag’s market cap is $205.81B.
When is Novartis Ag’s upcoming earnings report date?
Novartis Ag’s upcoming earnings report date is Apr 29, 2025 which is in 56 days.
How were Novartis Ag’s earnings last quarter?
Novartis Ag released its earnings results on Jan 31, 2025. The company reported €1.9 earnings per share for the quarter, beating the consensus estimate of €1.732 by €0.168.
Is Novartis Ag overvalued?
According to Wall Street analysts Novartis Ag’s price is currently Undervalued.
Does Novartis Ag pay dividends?
Novartis Ag pays a Annually dividend of €2.356 which represents an annual dividend yield of 2.93%. See more information on Novartis Ag dividends here
What is Novartis Ag’s EPS estimate?
Novartis Ag’s EPS estimate is 1.96.
How many shares outstanding does Novartis Ag have?
Novartis Ag has 2,189,930,400 shares outstanding.
What happened to Novartis Ag’s price movement after its last earnings report?
Novartis Ag reported an EPS of €1.9 in its last earnings report, beating expectations of €1.732. Following the earnings report the stock price went up 4.124%.
Which hedge fund is a major shareholder of Novartis Ag?
Currently, no hedge funds are holding shares in DE:NOTA
---
Novartis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€120.36 (17.42% Upside)
€120.36 (17.42% Upside)
Blogger Sentiment
Bullish
DE:NOTA Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
9.29%
12-Months-Change
Fundamentals
Return on Equity
26.33%
Trailing 12-Months
Asset Growth
2.83%
Trailing 12-Months
Company Description
Novartis Ag
Novartis AG develops, manufactures and sells healthcare products. Its two reporting segments are: Innovative Medicines and Sandoz. The Innovative Medicines business develops and sells patented prescription medicines and is made up of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
---
NOTA Company Deck
---
NOTA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong financial performance by Novartis with significant growth in key segments such as Entresto, Cosentyx, and Kisqali, along with robust pipeline advancements. However, there are concerns about potential generic entries impacting future performance and a delay in the OAV101 IT study. Overall, the positive achievements and growth in various segments outweigh the challenges highlighted.Read More>---
NOTA Stock 12 Month Forecast
Average Price Target
€120.36
▲(17.42% Upside)
Technical Analysis
Bristol-Myers Squibb
―
Eli Lilly & Co
―
Johnson & Johnson
―
Merck & Company
―
Pfizer
―
Best Analysts Covering NOTA
1 Year
1 Year Success Rate
1/1 ratings generated profit
1 Year Average Return
+5.30%
reiterated a buy rating 3 months ago
Copying Etzer Darout's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +5.30% per trade.
---